Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under‐prescription of beta‐blockers. Consequently, additional effective therapies are...

Descripción completa

Detalles Bibliográficos
Autores principales: Dewan, Pooja, Docherty, Kieran F., Bengtsson, Olof, de Boer, Rudolf A., Desai, Akshay S., Drozdz, Jaroslaw, Hawkins, Nathaniel M., Inzucchi, Silvio E., Kitakaze, Masafumi, Køber, Lars, Kosiborod, Mikail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Petrie, Mark C., Ponikowski, Piotr, Sabatine, Marc S., Schou, Morten, Sjöstrand, Mikaela, Solomon, Scott D., Verma, Subodh, Jhund, Pardeep S., McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Clinical Trials: Dapa‐hf
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247863/
https://www.ncbi.nlm.nih.gov/pubmed/33368858
http://dx.doi.org/10.1002/ejhf.2083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247863/
https://www.ncbi.nlm.nih.gov/pubmed/33368858
http://dx.doi.org/10.1002/ejhf.2083

Ejemplares similares